Nebenwirkungen · Poherdy
Poherdy 420 mg concentrate for solution for infusion. · Abschnitt 4.8 · PDF-Seite 9
HOS-153630 · Präparat HOS-101026
Table 2 summarizes the ADRs from the pertuzumab-treated groups of the following pivotal clinical trials: • CLEOPATRA, in which pertuzumab was given in combination with docetaxel and trastuzumab to patients with metastatic breast cancer (n=453) • NEOSPHERE (n=309) and TRYPHAENA (n=218), in which neoadjuvant pertuzumab was given in combination with trastuzumab and chemotherapy to patients with locally advanced, inflammatory, or early breast cancer • APHINITY, in which adjuvant pertuzumab was given in combination with trastuzumab and anthracycline-based or non-anthracycline-based, taxane-containing chemotherapy to patients with early breast cancer (n=2364)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-14T12:22:00Z · SHA-256 e51bba73aa849edde25c8bb5504db0140aa175ccec2e74e1ff7ef3ea305b337a · Passage caccf4c516fcf00b48b01bad89a74b3e2aa97190dd62d143f2dba42ad66ec493 · Zeichen 748–1464 im Abschnitt